World Contraceptives Markets

World Contraceptives Markets

This report analyzes the worldwide markets for Contraceptives in Millions of US$. The specific product segments analyzed are Oral Contraceptives, Condoms, Implants/ Injections, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 165 companies including many key and niche players worldwide such as Ansell Limited, Barr Pharmaceuticals, Inc., Church & Dwight Co. Inc., Conceptus, Inc., Condomi Health International GmbH, Female Health Company, Fuji Latex Co., Johnson & Johnson, Ortho-McNeil Pharmaceutical Inc, Okamoto Industries, Inc., Schering-Plough Corporation, Organon USA Inc, Bayer Schering Pharma AG, SSL International PLC, Warner Chilcott PLC, and Wyeth Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

TENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Oral Contraceptives I-3
Condoms I-3
Implants/Injections I-4
Other Contraceptives I-4


II. EXECUTIVE SUMMARY

1. Outlook II-1
Table 1: Global Contraceptive Market (2004): Percentage Market
Share Breakdown of Leading Players - Schering AG, Johnson &
Johnson, Barr Pharmaceuticals, Akzo Nobel, Watson Labs, Wyeth
Laboratories, and Others (includes corresponding Graph/Chart) II-2
Multifunctional Modern Contraceptives Make a Foray II-3
Top 5 Brands in the World Hormonal Contraceptives Market As of
the Year 2005 II-3
Extensive Distribution Drives growth of Contraceptive Products II-3
Advertising for Contraceptives Acquires A Whole New Dimension II-4
Manufacturers & Retailers Work in Sync to Accelerate Sales II-4
Innovation Keeps the Fire Burning for the Condoms Market II-4
Hormonal Contraceptives - Select Trends II-5
Table 2: Global Female Contraception Market (2004):
Percentage Share Breakdown of Select Geographic Markets -
United States, Europe, Latin America/ Canada, Japan, and Rest
of World (includes corresponding Graph/Chart) II-5
Generic & Biosimilar Contraceptive Products Gain Ground II-5
Generics Manufacturers II-5
Key Players in the Generic Hormonal Contraceptives Market II-6
Select Players in the Branded Biosimilar Hormonal
Contraceptives Market in Developing Countries II-6
OTC Hormonal Contraceptives - An Attractive Market II-6
R&D Companies & Generic Manufacturers - Developing Countries II-6
Commercial Success of R&D Brands Sustain Developmental
Programs in Developing Countries II-7
Challenges Facing Generic Contraceptive Products Manufacturers II-8

2. Product Overview and Analysis II-9
Types of Contraception II-9
The Contraceptive Timeline II-9
Table 3: World Contraceptive Prevalence (2005): Percentage
Use of Select Contraception Methods In Less Developed and
Developed Regions - Traditional Method, Pill, IUD, Condom,
Implant/Injectables, Male Sterilization, Female
Sterilization (includes corresponding Graph/Chart) II-10
Classification II-10
By Function II-10
Barrier Contraceptives II-10
Characteristic Features of Barrier Methods II-10
Hormonal Contraceptives II-11
Prescription Contraceptives II-11
Oral Contraceptives II-11
Overview of Oral Contraceptives - Benefits Vs. Risks II-12
Usage Levels of OCs in Worldwide Scenario II-12
Table 4: Percentage of Women in the age group 15-49 using
contraception across select regions and countries for the
years 2005 and 2006 II-13
Traditional and Modern II-14
Reversible and Permanent II-14
Table 5: Birth Control Methods and their Use in Major
Regions Worldwide II-15
Contraception - Levels of Effectiveness II-15
Table 6: Effectiveness Index of Contraceptive Measures II-15
Unmet Need for Contraception II-18
Table 7: Worldwide Contraceptives Market: Percentage Share
of Unmet Needs (Recent Past Data for 2003) - for Kenya, NE
Brazil, Pakistan, Senegal, Turkey, Colombia, Nigeria, Egypt,
Indonesia and Morocco (includes corresponding Graph/Chart) II-18
Segmental Analysis II-18
A.Condoms II-18
Overview II-18
Categories II-18
Latex Condoms II-19
Non-Latex Condoms II-19
Skin Condoms II-19
Polyurethane (PU) Condoms II-19
Table 8: Leading Product Types in the US Condoms Market
(2005) -Percentage Share Breakdown for Latex,
Synthetic/Polyurethane and Natural (includes corresponding
Graph/Chart) II-19
Comparison Between Polyurethane & Latex Condoms II-20
Male Condom - Effectiveness of Protection Against STDs II-20
Myths & Facts II-20
Selection & Effective Use of Condoms II-21
Condoms in the War Against AIDS II-21
Highlights II-21
Growth Factors II-22
Factors Hindering Wide Spread Use of Condoms II-22
Measures Aimed at Increasing Usage II-22
Female Condoms II-23
Who are the Main Users? II-23
Reality - An Effective Female Condom II-23
Market Shares: Year 2002 & 2003 II-24
Table 9: Worldwide Condoms Market: Leading Players
(Recent Past Data for 2002 & 2003) - Percentage Share
Breakdown by Value Sales - SSL, Ansell, Church & Dwight,
Okamoto, and Others (includes corresponding Graph/Chart) II-24
B.Oral Contraceptives (OCs)/Pills II-24
A Peep into the Past II-24
Synthetic Oral Contraceptives II-25
Characteristic Features of Oral Contraceptives (OCs) II-25
Top Brands/Manufacturers of Oral Contraceptive Formulations
Containing Levonorgestrel 0.15 MG/ Ethinyl Estradiol 30 mcg II-26
Table 10: Leading Methods of Contraception Worldwide -
Female sterilization, Intrauterine devices, Oral
contraceptives, Condom, Male Sterilization, Injectable
contraceptives, and Others (includes corresponding
Graph/Chart) II-27
Bayer Schering Pharma’s “Yasmin”: A Resounding Brand Worldwide II-27
Table 11: Sales of Bayer Schering Pharma AG's Yasmin, and
Yaz for the Years 2007 and 2009 (In Euro Millions) II-28
Advantages of Using OCs II-28
Table 12: Leading Methods of Contraception Worldwide -
Female sterilization, Intrauterine devices, Oral
contraceptives, Condom, Male Sterilization, Injectable
contraceptives, and Others (includes corresponding
Graph/Chart) II-29
Effects of Long-Term Use of Ocs II-29
Use of OCs/Pills - Myths & Facts II-29
Oral Contraceptives - Challenges & Strategies to Overcome
Problems II-30
Factors Associated with Failure of OCs/Pills II-30
Health Conditions to be Addressed when Using OCs II-30
Understanding Risks Associated with Use of OCs II-31
Cardiovascular Disease - A Major Side Effect of OC II-31
Intake of OCs Result in High Blood Pressure II-32
Smoking Intensifies Respiratory Problems in Pill Users II-32
Complications Arising by Use of OCs Directly Related to Age II-32
Relation Between the OC and Cancer II-32
Depression Linked to Use of OCs II-32
OCs Increases Osteoporosis Risk at Later Stage II-32
OCs May Reduce Sex Drive II-33
Effects of Pill on Childbearing Capacity II-33
Visiting a Doctor - Highly Recommended in Case of Warning
Symptoms II-33
Emergency Contraception (EC) - A New Face of Ocs II-33
Role of ECPs II-34
Effectiveness of ECP II-34
Different Types of EC Products II-34
Mini Pills II-34
RU486 - the French Abortion Pill II-35
Top Brands/Manufacturers of Emergency Contraceptive Pills
Containing Levonorgestrel 0.75 mg II-35
Top Brands/Manufacturers of Emergency Contraceptive Pills
Containing Levonorgestrel 10.25mg and Ethinyl Estradiol
50mcg II-36
Availability of Hormonal Contraceptives as OTC Drugs II-36
C.Injectable Contraceptives II-36
Depo-Provera II-37
Characteristic Features of Injectable Contraceptives II-37
Injectables - Challenges & Strategies to Overcome Problems II-38
Top Brands & Manufacturers of Two & Three Month Injectable
Contraceptive Formulations Containing Depot
Medroxyprogesterone Acetate (DMPA), and Norethisterone
Enanthate II-38
Top Brands & Manufacturers of Monthly Injectable
Contraceptive Formulations Containing (Norethisterone
Enanthate 50 mg and Estradiol Valerate 5 mg), (Dihydroxy
Progesterone Acetophenide 75 mg and Estradiol Enanthate
5 mg), (Medroxyprogesterone Acetate 25 mg and Estradiol
Cypionate 5 mg), (Algeston acetophenide 150 mg and
Estradiol Enanthate 10 mg), and Hydroxiprogesterone
Caproate 250 mg II-39
D.Intrauterine Devices (IUDs)/Implants II-40
Product Categories II-40
CopperT 380A (ParaGard) II-40
Progesterone T (or Progestasert) II-41
Characteristic Features II-41
Benefits II-41
Side Effects II-42
Challenges & Strategies to Overcome Problems II-42
Table 13: IUD Users Worldwide (2005): Percentage Breakdown
by Select Geographic Country/Region (includes corresponding
Graph/Chart) II-43
Long-term Reversible Contraceptive Implants II-43
Products II-43
Norplant II-43
Implanon II-44
Mirena II-44
Characteristic Features of Implantable Contraceptives II-44
Challenges & Strategies to Overcome Problems II-45
E.Spermicides II-45
Product Categories II-45
Benefits II-46
Drawbacks II-46
Contraceptive Foam II-46
Delfen Contraceptive Foam II-46
Contraceptive Cream or Jelly II-46
Encare Ovals II-46
F.Diaphragms II-46
G.Withdrawal & Douching II-47
H.Sterilization II-47
Tubal Ligation II-47
Reasons Behind Adoption II-48
Risk of Complications II-48
Types II-48
Abdominal Procedures II-48
Laparoscopy II-48
Mini-Laparotomy II-49
Laparotomy II-49
Vaginal Procedures II-49
Culdoscopy II-49
Colpotomy II-49
Hysterectomy - A High Risk Surgery II-49
Selective Tubal Occlusion Procedure (STOP) II-50
Vasectomy II-50
Method of Working II-50
Reasons Behind Adoption II-51
Risk of Complications II-51
I.Other Contraceptive Methods II-51
Contraceptive Sponges II-51
Today Sponge II-52
Characteristic Features of Today Sponge II-52
Table 14: Efficiency Rates of Today Sponge Based on Usage
for 12-Month Period (includes corresponding Graph/Chart) II-53
Allendale Pharmaceuticals II-53
Protectaid Sponge II-53
Characteristic Features of Protectaid Sponge II-54
Cervical Caps II-54
Pros and Cons of the Device II-54
Vaginal Contraceptive Film (VCF) II-55
Contraceptive Vaccine II-55
Ortho Evra Weekly Contraceptive Patch II-55
NuvaRing Monthly Vaginal Ring II-55

3. Research and Development II-56
University of Kansas Conducts Research on the Male Pill II-56
Clinical Trial of Contraceptive Spray II-56
Oral Contraceptive Minimizes Premenstrual Syndrome Symptoms as
per New Study II-57
Indian Scientists in Process of Developing First Herbal
Contraceptive Pill II-57
Cause of Infertility - Not Associated with IUDs II-57
Effectiveness of Norplant (Levonorgestrel implant) II-57
Presence of Estrogen in OCs Offers Protection from Colorectal
Cancer II-58
Hormonal Contraceptive Usage & Risk Associated with Certain STDs II-58
Use of Third Generation OCs Increases Risk of Blood Clots II-58
High Risk of Deep Vein Thrombosis with Cyproterone-Containing OCs II-58

4. Role of United Nations in Promoting use of Contraceptives II-59
Female Condoms Reach New Heights with Aid from UNAIDS II-59
Donor Support for Contraceptive Commodity II-59
Table 15: Total Cost of Contraceptives and Condoms:
2000-2010P (includes corresponding Graph/Chart) II-59
Unmet Need II-60
Table 16: Donor Support by Region: 2004 (includes
corresponding Graph/Chart) II-60
Table 17: Contraceptive Donor Support for STI/HIV Prevention
by Agency: 1997-2004 II-60
Donor Support by Contraceptive Method II-61
Table 18: Donor Support by Contraceptive Method: 2000-2004
(includes corresponding Graph/Chart) II-61

Table 19: Donor Support for Contraceptive Method by Agency:
2000-2004 (includes corresponding Graph/Chart) II-61
Donor Support by Top Ten Countries II-62
Table 20: Major Donor Support Recipient Countries: 2004
(includes corresponding Graph/Chart) II-62
Table 21: Donor Support for Condoms and Other Contraceptive
Commodities: 1997-2004 (includes corresponding Graph/Chart) II-62
Donor Funding For Male Condoms II-63
Table 22: Donor Funding For Male Condoms: 2000-2004 (includes
corresponding Graph/Chart) II-63

Table 23: Donor Funding For Male Condoms by Region: 2004
(includes corresponding Graph/Chart) II-63

Table 24: Number of Male Condoms Supplied by Donors:
Region-Wise Breakup for year 2004 II-64

Table 25: Donor Support for Condoms (1995-2004): Number of
Condoms by Donor - USAID, UNFPA, BMZ/KfW, DFID, EU, DKT, PSI,
IPPF, MSI, Netherlands, SIDA, and Japan (In Thousand Units)
(includes corresponding Graph/Chart) II-65

Table 26: Donor Funding for Condoms (1995-2004): Number of
Condoms by Donor - USAID, UNFPA, BMZ/KfW, DFID, EU, DKT, PSI,
IPPF, MSI, Netherlands, SIDA, and Japan (In US$ 000)
(includes corresponding Graph/Chart) II-66

Table 27: Total Number of Female Condoms in Private and
Public Sectors: Region-wise Split from Years 1997 through
2004 (includes corresponding Graph/Chart) II-66

Table 28: Percentage of Couples Using Condoms for Family
Planning (2005) by Region II-67
Use of Modern Contraceptives Grows in Developing Regions II-69
Table 29: Estimated Numbers of Contraceptive Users in
Developing Nations: 2000-2015 (includes corresponding
Graph/Chart) II-69

Table 30: Comparative Study of Modern Contraception Methods
in Developing Regions (including India & China) and
Developing Regions (excluding India & China) - Percentage of
Married Women Using Oral Contraceptives, Female
Sterilization, and Intrauterine Devices (IUDs): Recent Past
Data for 2000 (includes corresponding Graph/Chart) II-70
Difference in Usage of Oral Contraceptives in Developed and
Developing World II-70
Table 31: Oral Contraceptives Usage by Married and Sexually
Active Unmarried Women (Aged 15-49 years) in Developed
Regions including North America, Eastern Europe & Central
Asia, and Australia & New Zealand: Recent Past Data for 2000 II-70

Table 32: Oral Contraceptives Usage by Married and Sexually
Active Unmarried Women (Aged 15-49 years) in Developing
Regions including Asia, Near East & North Africa, Sub-Saharan
Africa, Pacific Rim, and Latin America & Caribbean: Recent
Past Data for 2000 (includes corresponding Graph/Chart) II-70
Prevalence of Contraceptive Methods II-71
Table 33: Increase in Contraceptive Usage by 2005 -
Percentage Share Growth by Asia, Latin America and Africa
(includes corresponding Graph/Chart) II-71

Table 34: Worldwide Contraceptives Market: Estimated Number
of Users (2015 & 2025) - Asia, Latin America and Africa
(includes corresponding Graph/Chart) II-71

Table 35: Worldwide Contraceptive Market: Prevalence Amongst
Women (2000-2025) - Percentage Share by Asia, Latin America
and Africa (includes corresponding Graph/Chart) II-72
United Nations Population Fund (UNFPA) II-72
UNFPA Gets Aid from Britain to Help Developing World II-73
Rise in Cost of Providing Contraceptives II-73
Future Trends Worldwide II-74

5. New Product Introductions/Innovations II-75
FHI and HLL Launch Aastha Condom II-75
NATCO Launches World-Class Oral Contraceptive II-75
Bayer Plans Launch of Mirena in Japan II-75
Barr Pharmaceuticals Unveils Generic Version of SEASONALE® II-75
PSI Launches Trust Condoms in Uganda II-75
Tanzania Marketing and Communication Launches a New Brand of
Condoms II-76
German Group to Launch Innovative Spray-on Condom II-76
Hindustan Latex Unveils First-Ever Female Condom in Indian Market II-76
Church & Dwight’s Trojan Launches Unique Twister Condom II-76
Berlex Inc. Introduces New Oral Contraceptive in the United
States II-76
Hindustan Latex Launches the Moods ‘Get Closer Pack’ II-76
Warner Introduces First-of-its-Kind Chewable Oral Contraceptive II-77
Warner Announces FDA Approval for Loestrin® 24 Fe
Contraceptive Pill II-77
Huge Brand Unveils "Huge" Brand of Condoms II-77
Private Media Group and Zemtex Introduces Private Brand of
Condoms II-77
Hindustan Latex Launches New Varieties of ‘Moods’ Condom II-78
Organon Introduces Marvelon 21, Oral Contraceptive in Japan II-78
GlaxoSmithKline India Unveils Elogen, a Low Dose Contraception
Pill II-78
USAID’s T-MARC Launches Two Female Contraceptives in Tanzania II-78
SMC Plans to Introduce First Implantable Male Contraceptive II-79
Zimbabwe in Alliance with Indian Company Launches New Oral
Contraceptive Products II-79
Global Protection Adds “ONE Condoms(C)” to its Product Line II-79
Hubei Pharmaceutical Launches a New Contraceptive II-79
Intellx Inc Announces Expansion of VA Women's Condom II-79
DKT Ethiopia Re-Launches Sensation Condoms II-79
Transdermal Contraceptive Spray under Clinical Testing by
Population Council and Acrux II-79
Prasco Launches Cesia, a New Generic Oral Contraceptive II-80
FHC Launches Female Condom in India II-80
FHC Files Patent for Second-Generation Version of the Female
Condom II-80
FHCO Enters into Agreement with USAID II-80
Barr Laboratories Launches Extended-Cycle Oral Contraceptive,
Seasonale II-80
Central Drug Research Institute to Launch Consap II-81
Johnson & Johnson Introduces Evra in UK II-81
Allendale Pharmaceuticals Relaunches Today Sponge II-81
New V-Amour Women's Condom Introduced in Germany II-81
Durex Introduces Intense Sensation Condoms II-81
Durex Launches Performax Condoms II-81
Ortho-McNeil Introduces Ortho Evra II-81
Pasante Healthcare Launches Pasante Condoms Range II-82
Hindustan Latex Debuts New Lubricated Condoms II-82
Durex Launches 'Easy-on' line of Condoms II-82
Rayson Healthcare Introduces new Condom Brand II-82
Ansell healthcare Unveils Contempo Lubricated Latex Condoms II-82
Church & Dwight Launches Trojan Her Pleasure Premium Latex
Condoms II-82
Pharmacia Introduces Depo-Provera contraceptive in 1ml vials II-82
Organon Debuts NuvaRing contraceptive II-82
Organon Laboratories Introduces Cerazette II-83
Barr Rolls Out Lessina Contraceptive Tablets II-83
Schering Introduces Yasmin Across the US and Europe II-83
Condomania Introduces New Packaging II-83
Condomania Launches Newly Designed, InSpiral Condoms II-83
Condomania Introduces Pleasure Plus Condoms II-83
Durex Consumer Launches Two New Varieties II-83
Church & Dwight’s Consumer Products Division Launches Two
Innovative Products II-83
Ansell Launches LifeStyles Luscious Flavors Condoms II-84
Trojan Introduces Extended Pleasure Premium Latex Condoms II-84
JK Ansell Launches New Sub-Brand, Kamasutra Sport II-84
JK Ansell Launches Kamasutra Xtra Pleasure Condoms II-84
TTK-LIG Launches Pink Version of Kohinoor Luxury Condoms II-84
Condomi Launches Vegan-Friendly Condoms in UK II-84
Berlex Launches Mirena in US II-84
Schering Introduces Levonelle in UK II-85
Organon Launches Cyclessa II-85
Barr Laboratories Launches New Generic Oral Contraceptives in
the US II-85
Duramed Introduces New Oral Contraceptives in the US II-85
American Pharmaceutical Partners Launch New Product II-85
Swiss Health Launches Vitex Agnus Castus II-85
Sun Pharmaceutical Launches Puregest Progesterone Capsules II-85

6. Recent Industry Activity II-86
Organon Licenses Spray Technology from Acrux II-86
BioSante Initiates Phase II Trials of Oral Contraceptives II-86
YAZ® Receives FDA Approval for New Indication II-86
Paladin Labs Receives Approval to Market SEASONALE® II-86
ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) Receives Two
FDA Approvals (USA) II-87
Conceptus Receives FDA Approval for Third-Generation Essure ®
Procedure II-87
Wyeth Receives FDA Approval for Lybrel ™ II-87
NuvaRing® Completes European Authorization in 13 Countries II-87
HLL Expands Promotion of Female Condom II-87
ChrysCapital Gains Minority Stake in Mankind Pharma II-88
7 Chemicals Inks Deal with Ferring Pharmaceuticals II-88
Synova Acquires Allendale Pharmaceuticals and Global Rights to
Today Sponge II-88
Ansell Pockets Blowtex II-88
Bayer Merges with Berlex to Establish Bayer HealthCare
Pharmaceuticals II-88
UNFPA Releases Pacific-Design Condoms II-89
Wyeth Completes Acquisition of Wyeth K.K. Japan II-89
Conceptus, Inc. to Acquire Conceptus SAS II-89
Warner Chilcott Company Enters into a Supply Agreement with
Watson Pharma II-89
SSL International Fully Acquires Qingdao London Durex Co Ltd II-89
Bayer HealthCare Takes Over Marketing/Distribution Network of
Pharmonyx Ltd. II-89
USFDA Grants OTC Status Plan B (R) II-90
Ethiopia Enters into Agreement with UNFPA and UNICEF II-90
YAZ® Receives FDA Approval II-90
FHC Receives USAID Orders II-90
FHC Signs MoU with Hindustan Latex Ltd. II-90
IMPLANON™ Receives US FDA Approval II-91
Watson Pharmaceuticals Receives Approval for Generic Version
of Seasonale® II-91
Watson Pharmaceuticals Receives Approval for Generic Version
of Levlite® II-91
Ansell Acquires Stake in Wuhan Jissbon Sanitary Products II-91
Ansell Acquires Unimil of Poland II-91
Conceptus Joins Hands with Gyrus and Olympus on Hysteroscopy II-91
Watson Acquires Andrx II-92
Bayer Acquires Schering AG II-92
Duramed Acquires FEI II-92
Schering and Organon to Terminate Research Collaboration II-93
ACR Extends Existing Agreement with Population Council II-93
Antares Inks Contraceptive Development Agreement with
Population Council II-93
FHC to Enhance Manufacturing Capacity of FC2 Female Condom II-93
Medevice 3S Establishes Condom Manufacturing Facility II-94
SSL International to Acquire Additional 50% Stake in Qingdao
London Durex in China II-94
Female Health Company Signs an Agreement with Fuji Latex II-94
Female Health Company Obtains Order for the Supply of Female
Condoms from India II-94
Conceptus Receives Cigna’s Approval for Reimbursement of
Essure Procedure II-94
Barr Pharmaceuticals Obtains FDA Approval for Duramed's
SEASONIQUE™ Oral Contraceptive II-95
Schering AG Receives European Approval for Yasminelle®
Contraceptives II-95
AMMD Takes Over Ovion II-95
Duramed Pharmaceuticals Enters into a License and Distribution
agreement with Paladin II-95
Female Health Company Bags Brazilian Order for FC Female Condoms II-95
Female Health Company Enters into an Agreement with the World
YWCA for Distribution of FC2 Female Condoms™ II-96
Akzo Nobels Receives Development and Marketing Rights for EMM
310066 Contraceptive II-96
Conceptus and Gynecare Terminates their Sole Co-Promotion
Agreement II-96
FTC Sues Warner Chilcott and Barr II-96
Acrux Concludes Phase I Clinical Trial for Spray on Contraceptive II-96
Vulkan and CPR to Set Up a Joint Venture for the Production of
Condoms II-96
Warner Chilcott Acquired by Investment Group II-96
Brazil Based Sao Roque Condoms Plant to Expand Production
Capacity II-97
Berlex Receives Approval for Yasmin Tablets in Canada II-97
Mochida Pharmaceutical to Exclusively Distribute Ortho 777-21
and OrthoM-21 in Japan II-97
Barr Laboratories Obtains Approval for Demulen Tablet II-97
Clinical Trials on Male Contraceptive II-97
FHC Receives Distribution Order from South Africa II-97
China to Purchase Contraceptives Worth US$ 45.7 Million II-97
Female Health Company Signs Agreement with BZP II-98
Duramed Acquires Exclusive Rights to Nordette® from King
Pharmaceuticals II-98
Berlex Laboratories Inc. Renamed Berlex, Inc. II-98
Duramed Pharmaceuticals Acquire Rights to Loestrin (R) from Galen II-98
Galen Receives Option to License Barr’s Generic Ovcon (R) 35 II-98
Barr Acquires Shares of Women’s Capital Corporation II-99
Galen Signs a Licensing Agreement with Barr II-99
Galen Acquires Pfizer Manufacturing Facility II-99
Polar Pharma to Expand Production Capacity and Re-launch ‘
Adam’ Condoms II-100
Prasco Signs an Agreement with Organon II-100
Pfizer Acquires Pharmacia Corp II-100
Teva and Andrx in Collaborative Arrangement II-100
Barr Laboratories Acquires Marketing Rights II-100
Barr Laboratories Signs Mutual Agreement with Galen II-100
Pfizer Sells Women's Health Care Products to Galen II-101
FDA Approves Ovcon 35 II-101
Barr Obtains FDA Approval for ANDA II-101
FHC Enters into an Agreement with HLL II-101
Watson Signs an Agreement with OMJ II-101
Ortho-McNeil Receives Approval for ORTHO TRI- CYCLEN LO II-102
American Home Products Restructures and Changes Name to Wyeth
Corporation II-102
Ansell Promotes the Fun Factor Embarks on ‘It Feels Right’
Campaign II-102
FDA’s Approval for Barr's generic Ortho-Cyclen Tablet II-102
Warner-Chilcott Acquires Two Healthcare Products from Bristol
-Myers II-103
Ansell Acquires Johnson & Johnson’s Canadian Condom Business II-103
SSL Acquires Joint Venture Partner in Seton Scholl Japan Ltd II-103
CSI Acquires Plant in North Las Vegas for Condom Production II-103
Barr Laboratories Merges with Duramed Pharmaceuticals II-103
Condomi Enters into a Strategic Joint Venture II-103
Condomi in Alliance with MCM II-104
FHC Enters into Supply Contract in Brazil II-104
FHC Secures Contract from UNFPA II-104
FHC Receives Contract from South African Health Department II-104
Carter Wallace Divests Consumer Brands to Armkel II-105
SSL Restructures Business Operations II-105
FHC Renames Female Condom II-105
US Branch of SSL International Group Renamed II-105

7. Focus on Select Players II-106
Ansell Limited (Australia) II-106
Barr Pharmaceuticals, Inc. (US) II-106
Church & Dwight Co Inc (US) II-106
Conceptus Inc (US) II-107
Condomi Health International GmbH (Germany) II-107
Female Health Company (US) II-107
Fuji Latex Co (Japan) II-107
Johnson & Johnson (US) II-108
Ortho-McNeil Pharmaceutical Inc (US) II-108
Okamoto Industries Inc (Japan) II-108
Schering-Plough Corporation (US) II-109
Organon USA Inc (US) II-109
Bayer Schering Pharma AG (Germany) II-109
SSL International PLC (UK) II-109
Warner Chilcott PLC (US) II-110
Wyeth Corporation (US) II-110

8. Global Market Perspective II-111
Table 36: World Recent Past, Current & Future Analysis for
Contraceptives by Geographic Region- US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-111

Table 37: World Long-term Projections for Contraceptives by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-112

Table 38: World 10-Year Perspective for Contraceptives by
Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets for Years 2000, 2007 &
2010 (includes corresponding Graph/Chart) II-113

Table 39: World Recent Past, Current & Future Analysis for
Oral Contraceptives by Geographic Region- US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-114

Table 40: World Long-term Projections for Oral Contraceptives
by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-115

Table 41: World 10-Year Perspective for Oral Contraceptives by
Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets for Years 2000, 2007 &
2010 (includes corresponding Graph/Chart) II-116

Table 42: World Recent Past, Current & Future Analysis for
Condoms by Geographic Region- US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-117

Table 43: World Long-term Projections for Condoms by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-118

Table 44: World 10-Year Perspective for Condoms by Geographic
Region- Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World Markets for Years 2000, 2007 & 2010
(includes corresponding Graph/Chart) II-119

Table 45: World Recent Past, Current & Future Analysis for
Implants/Injections by Geographic Region- US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-120

Table 46: World Long-term Projections for Implants/Injections
by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-121

Table 47: World 10-Year Perspective for Implants/Injections by
Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets for Years 2000, 2007 &
2010 (includes corresponding Graph/Chart) II-122

Table 48: World Recent Past, Current & Future Analysis for
Other Contraceptives by Geographic Region- US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-123

Table 49: World Long-term Projections for Other Contraceptives
by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-124

Table 50: World 10-Year Perspective for Other Contraceptives
by Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets for Years2000, 2007 &
2010 (includes corresponding Graph/Chart) II-125


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Outlook III-1
Restraints III-1
Major Market Trends III-1
Changing Consumer Demographics III-1
Relentless Promotional Programs Drive Home the Point III-2
Use of Intimacy Products on the Rise III-2
Table 51: US Contraceptives Ad Spend (2005): Percentage
Breakdown by Dollars Spent on Radio, Out of Home
Advertising, Television, Magazine, and Newspaper (includes
corresponding Graph/Chart) III-2
Generics Ransack the Branded Market III-3
Condoms - A ‘Fun, Inviting and Pleasurable’ Way to Healthy
Life and Lifestyle III-3
Trojan Dominates the Condoms Market in the US III-3
Market Share Statistics III-4
Table 52: US Market for Male Contraceptives: Percentage
Breakdown of Retail Dollar Sales of Key Players for the
Year Ended January 2007 (includes corresponding
Graph/Chart) III-4

Table 53: US Market for Male Contraceptives: Breakdown of
Retail Unit Sales of Key Players for the Year Ended January
2007 (In 000 Units) (includes corresponding Graph/Chart) III-4

Table 54: US Market for Female Contraceptives: Percentage
Breakdown of Retail Dollar Sales of Key Players for the
Year Ended January 2007 (includes corresponding
Graph/Chart) III-5

Table 55: US Market for Female Contraceptives: Percentage
Breakdown of Retail Unit Sales of Key Players for the Year
Ended January 2007 (includes corresponding Graph/Chart) III-5

Table 56: US Market for Female Contraceptives: Percentage
Breakdown of Dollar Sales of Leading Brands for the Year
Ended March 2005 (includes corresponding Graph/Chart) III-5
Noticeable Shift in Retail Marketing Techniques III-5
Rising Use of Condoms Amongst Teenagers III-6
Changing Attitudes and Perceptions Drive Market Sales III-6
Pill Continues to be One of the Most Popular Forms of
Contraception III-7
Table 57: Leading Methods of Contraception in the US :
Percentage Breakdown by Method of Contraception for Oral
Contraceptives, Condoms, Female Sterilization, Male
Sterilization, Withdrawal, Injectables, Rhythm,
Intrauterine Devices, Other(s), and No Method Followed
(includes corresponding Graph/Chart) III-7
Oral Contraceptives and its Shades of Grey III-8
Marketing Efforts Aimed at Influencing Female College Students III-8
Condoms Continuing Canter III-8
Table 58: US Condoms Market (Recent Past Data for 2003):
Consumer Purchasing Patterns for Condoms at All Retail
Outlets, Drug Stores, Supermarkets, Supercenters, and
Discount Stores (includes corresponding Graph/Chart) III-9
Drug Stores Remain the Choice for Contraceptive Needs III-9
Trade Class Statistics III-9
Table 59: Leading Male Contraceptives Brands in the US
(2005) - Percentage Share Breakdown by Sales Revenues
through Drug Stores - Trojan, Trojan Enz, Trojan Magnum,
LifeStyles, Durex Extra Sensitive, Trojan Her Pleasure,
Kling-Tite Naturalamb, Durex and *Others (includes
corresponding Graph/Chart) III-10

Table 60: Leading Male Contraceptive Brands in the US
(2005) - Percentage Share Breakdown by Volume Sales through
Drug Stores - Trojan, Trojan Enz, Trojan Magnum, Durex
Extra Sensitive, LifeStyles, Trojan Her Pleasure, Durex,
Trojan Supra and *Others (includes corresponding
Graph/Chart) III-10

Table 61: Leading Brands in the US Condoms Market (2004):
Percentage Share Breakdown by Trade Class (Supermarkets,
Drug Stores, and Discount Stores (Excluding Wal-Mart))
Sales for Trojan, Trojan Enz, Lifestyles, Durex Extra
Sensitive, Trojan Magnum, Trojan Ultra Pleasure, Trojan Her
Pleasure, Kling Tite Naturalamb, Trojan Extended Pleasure,
Lifestyles Ultra Sensitive, and Others (includes
corresponding Graph/Chart) III-11

Table 62: Leading Drug Store Brands in the US Condoms
Market (2003): Percentage Share Breakdown for Trojan,
Trojan Enz, LifeStyles, Trojan Magnum, Durex Extra
Sensitive, Kling Tite Natural Lamb, Trojan Her Pleasure,
Trojan Ultra Pleasure, Trojan Extended Pleasure, Durex, and
Others (includes corresponding Graph/Chart) III-12

Table 63: Leading Supermarket Brands in the US Condoms
Market (Recent Past Data for 2001-2003): Percentage Share
Breakdown by Trojan, Trojan-Enz, Lifestyles, Sheik Super,
Class-Act, Sheik-Classic, Naturalamb and Others (includes
corresponding Graph/Chart) III-13

Table 64: Leading Condom Brands in the US Market (Recent
Past Data for 2003): Percentage Breakdown by Trojan, Trojan
Enz, Lifestyles, Durex Extra Sensitive, Trojan Ultra
Pleasure, Kling Tite Natural lamb, Trojan Magnum, Durex
Ultimate Feeling, Trojan Supra and Durex High Sensation
(includes corresponding Graph/Chart) III-13

Table 65: Sales of Condoms Through Leading Distribution
Channels in the US (2005) -Drug Stores, Discount Stores and
Supermarkets (includes corresponding Graph/Chart) III-14

Table 66: Distribution Channel Percentage Share - US Male
Contraceptives (Recent Past Data for 2003 & 2002) - by
Chain Drug Stores, Discount Stores, Food/Drug Combination
Stores, Independent Drug Stores and Supermarkets (includes
corresponding Graph/Chart) III-14

Table 67: US Contraceptives Market: Average Price per Unit
of Male and Female Contraceptives for he Year 2006 (In US
$) III-14

Table 68: Total Contraceptives Market in the US (2005) -
Percentage Share Breakdown by Trade Class (Supermarkets,
Drug Stores, and Discount Stores (Excluding Wal-Mart))
Value Sales for Male Contraceptives and Female
Contraceptives III-15

Table 69: US Condoms Market: Percentage Breakdown of Dollar
Sales by Product Type for the Year Ended January 2006
(includes corresponding Graph/Chart) III-15
Oral Contraceptives - Unanimously the Choice of American Women III-15
Table 70: Contraceptive Features Preferred by Women in US
(includes corresponding Graph/Chart) III-15

Table 71: US Market for Oral Contraceptive Drugs (2004):
Percentage Breakdown of Dollar Sales of Leading Brands
(includes corresponding Graph/Chart) III-16

Table 72: US Market for Oral Contraceptive Drugs (2004):
Breakdown of Leading Brands by Total Number of
Prescriptions (TRx) (In Million) (includes corresponding
Graph/Chart) III-16

Table 73: US Oral Contraceptive Market: Percentage
Breakdown of Dollar Sales of Branded Oral Contraceptives
and Branded-Generic Oral Contraceptives for the Years 2002
& 2004 III-17

Table 74: US Market for New Prescription (NRx) Oral
Contraceptive (Estrogen/Progestogen-based) Drugs (2006):
Percentage Market Share Breakdown of Leading Players
(includes corresponding Graph/Chart) III-17

Table 75: US Market for Prescription (Rx) Oral
Contraceptives: Percentage Market Share Breakdown of
Leading Players for the Years 2007E and 2010(P) (includes
corresponding Graph/Chart) III-17

Table 76: US Prescription Contraceptives Market: Percentage
Market Share Breakdown for Select Product Categories for
the Years 2007E & 2010P (includes corresponding
Graph/Chart) III-18

Table 77: US Market for Prescription Extended Cycle Oral
Contraceptives: Percentage Market Share Breakdown for
Leading Brands for the Years 2007E & 2010P (includes
corresponding Graph/Chart) III-18
Export & Import Statistics III-19
Table 78: US Exports of Chemical Contraceptive Preparations
(Based on Hormones or Spermicides): Breakdown of Export
Value by Select Destination Countries for the Year 2006 (In
US $ Thousand) (includes corresponding Graph/Chart) III-19

Table 79: US Imports of Chemical Contraceptive Preparations
(Based on Hormones or Spermicides): Breakdown of Import
Value by Select Countries of Origin for the Year 2006(In US
$ Thousand) (includes corresponding Graph/Chart) III-20

Table 80: US Exports of Sheath Contraceptives made of
Vulcanized Rubber (other than hard rubber) : Breakdown of
Export Value by Select Destination Countries for the Year
2006(In US $ Thousand) (includes corresponding Graph/Chart) III-20

Table 81: US Imports of Sheath Contraceptives made of
Vulcanized Rubber (other than hard rubber): Breakdown of
Import Value by Select Countries of Origin for the Year
2006(In US $ Thousand) (includes corresponding Graph/Chart) III-21

Table 82: Contraceptives Market in the US: Leading Hormonal
Contraceptives (Recent Past Data for 2002) - Percentage
Share by Developer/Marketer: J&J, Wyeth Corp, Schering AG,
Akzo Nobel’s Organon, Pharmacia and Pfizer (includes
corresponding Graph/Chart) III-21
Health Facts III-22
Rising Use of Oral Contraceptives III-22
Abortion Control Drugs & Methods III-22
Medical Abortion III-22
a. Mifepristone - A Medical Breakthrough III-22
b. Methotrexate III-23
Expanding the Use & Availability of EC Drugs III-23
Pharmacies Sell ECPs III-23
Demographics III-23
Facts and Figures III-23
Sales of Contraceptives (Male & Female) - Family Planning
Category III-24
Insurance Coverage for Contraceptives Still in Contest III-24
Key Players III-24
Product Launches III-28
Strategic Corporate Developments III-31
B.Market Analytics III-43
Table 83: US Recent Past, Current & Future Analysis for
Contraceptives by Product Segment- Oral Contraceptives,
Condoms, Implants/Injections and Others Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-43

Table 84: US Long-term Projections for Contraceptives by
Product Segment - Oral Contraceptives, Condoms,
Implants/Injections and Others Markets Segments
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-43

Table 85: US 10-Year Perspective for Contraceptives by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Contraceptives, Condoms, Implants/Injections and Others
Markets for 2000, 2007 & 2010 (includes corresponding
Graph/Chart) III-44

2. Canada III-45
A.Market Analysis III-45
Scenario III-45
Efforts on Way to Launch Male Contraceptive Injection III-45
Outlook III-45
Condoms Market III-45
Immucon Obtains US Patent for Male Contraceptive Technology III-46
Exports & Import Statistics III-46
Table 86: Canadian Exports of Chemical Contraceptive
Preparations (Based on Hormones or Spermicides): Percentage
Breakdown of Export Value by Select Destination Countries
for the Year 2005 (includes corresponding Graph/Chart) III-46

Table 87: Canadian Imports of Chemical Contraceptive
Preparations (Based on Hormones or Spermicides): Percentage
Breakdown of Import Value by Select Countries of Origin for
the Year 2005 (includes corresponding Graph/Chart) III-47

Table 88: Canadian Exports of Sheath Contraceptives made of
Vulcanized Rubber (other than hard rubber): Percentage
Breakdown of Export Value by Select Destination Countries
for the Year 2005 (includes corresponding Graph/Chart) III-47

Table 89: Canadian Imports of Sheath Contraceptives made of
Vulcanized Rubber (other than hard rubber): Percentage
Breakdown of Import Value by Select Countries of Origin for
the Year 2005 (includes corresponding Graph/Chart) III-48
Strategic Corporate Developments III-48
B.Market Analytics III-49
Table 90: Canadian Recent Past, Current & Future Analysis
for Contraceptives by Product Segment- Oral Contrace